摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-methyl-5-phenyl-1,3-dihydro-pyrido[4,3-e][1,4]diazepin-2-one | 1422-08-8

中文名称
——
中文别名
——
英文名称
1-methyl-5-phenyl-1,3-dihydro-pyrido[4,3-e][1,4]diazepin-2-one
英文别名
2,3-dihydro-1-methyl-5-phenyl-1H-pyrido [4,3-e]-1,4-diazepine-2-one;2,3-dihydro-1-methyl-5-phenyl-1H-pyrido[4,3-e]-1,4-diazepine-2-one;1-Methyl-5-phenyl-1.3-dihydro-2H-pyrido<4.3-e>-1.4-diazepin-2-on;1-methyl-5-phenyl-3H-pyrido[4,3-e][1,4]diazepin-2-one
1-methyl-5-phenyl-1,3-dihydro-pyrido[4,3-<i>e</i>][1,4]diazepin-2-one化学式
CAS
1422-08-8
化学式
C15H13N3O
mdl
——
分子量
251.288
InChiKey
KSSXRQGGRNXJKO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    45.6
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Pharmaceutical preparation
    申请人:Merck & Company, Inc.
    公开号:US05776930A1
    公开(公告)日:1998-07-07
    A method of preventing, treating, terminating and protecting against cardiac arrhythmias, such as atrial, supraventricular and ventricular ectopy, tachycardia, flutter or fibrillation, including atrial, supraventricular and ventricular arrhythmias resulting from myocardial ischemic injury in a patient in need thereof, comprising administration of a selective I.sub.Ks antagonist and a beta-adrenergic receptor blocking agent, administered in combined therapy either simultaneously, separately or sequentially is presented. Additionally, a pharmaceutical preparation comprising a selective I.sub.Ks antagonist and a beta-adrenergic receptor blocking agent, wherein these compounds are administered simultaneously, separately or sequentially is presented.
    一种预防、治疗、终止和保护心律失常的方法,如心房、上室和室性异位搏动、心动过速、心房扑动或颤动,包括由心肌缺血损伤引起的心房、上室和室性心律失常,该方法包括给予选择性I.sub.Ks拮抗剂和β-肾上腺能受体阻滞剂,以联合疗法的形式同时、分开或依次给药。此外,还提供了一种药物制剂,包括选择性I.sub.Ks拮抗剂和β-肾上腺能受体阻滞剂,这些化合物可以同时、分开或依次给药。
  • Antiarrhythmic benzodiazepines
    申请人:Merck & Co., Inc.
    公开号:US05426185A1
    公开(公告)日:1995-06-20
    Benzo-(1,5)-diazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia. The compounds have structural formulae: ##STR1##
    苯并-(1,5)-二氮杂环衍生物在3位具有酰胺或脲功能,对心律失常的治疗具有用处。这些化合物的结构式如下:##STR1##
  • ANTIARRHYTHMIC BENZODIAZEPINES
    申请人:Merck & Co., Inc.
    公开号:EP0730454A1
    公开(公告)日:1996-09-11
  • EP0730454A4
    申请人:——
    公开号:EP0730454A4
    公开(公告)日:2003-06-04
  • US5426185A
    申请人:——
    公开号:US5426185A
    公开(公告)日:1995-06-20
查看更多

同类化合物

氯吡卓醇 利喷西平 丙吡西平 N-[(4-苯基-2,3,4,5-四氢-1H-吡啶并[2,3-b][1,4]二氮杂卓-2-基)甲基]苯甲酰胺 N-[(4-苯基-2,3,4,5-四氢-1H-吡啶并[2,3-b][1,4]二氮杂卓-2-基)甲基]乙酰胺 9-叠氮基-11-乙基-6-甲基吡啶并[3,2-c][1,5]苯并二氮杂卓-5-酮 5-甲基-11-(甲磺酰)-5,11-二氢-6H-二吡啶并[3,2-b:2',3'-e][1,4]重氮基庚英-6-酮 5,11-二氢-4-甲基-6H-二吡啶并[3,2-b:2',3'-e][1,4]二氮杂卓-6-酮 4-苯基-2-氧代-5-(2-(4-甲基哌嗪-1-基)乙酰基)-1H-四氢吡啶并[2,3-b][1,4]二氮杂卓 4-苯基-1,3,4,5-四氢-2H-吡啶并[2,3-b][1,4]二氮杂卓-2-硫酮 4-(吗啉-4-基甲基)-1H-吡啶并[2,3-e][1,4]二氮杂卓-2,3,5(4H)-三酮 4,5-二氢-1H-吡啶并[2,3-E][1,4]重氮基庚英-3(2H)-酮 3-苯基-2-氧代-5-(2-(4-甲基哌嗪-1-基)乙酰基)-1H-四氢吡啶并[2,3-b][1,4]二氮杂卓 3-(乙酰氧基)-7-氯-5-(2-氯苯基)-1,3-二氢-2H-吡啶并[3,2-e]-1,4-二氮杂卓-2-酮 3,4,6,7-四氢-10-氯-1-苯基-8H-吡啶并[3,2,1-jk][1,4]苯并二氮杂卓-4,8-二酮 2-甲基-5-(2-吗啉-4-基乙基)-3,5-二氢-4H-吡啶并[2,3-b][1,4]重氮基庚英-4-酮盐酸 1OH-吡啶并(3,2-d)噻吩并(3,2-e)(1,4)-重氮基庚英-10-酮,4,9-二氢-4-((4-甲基-1-哌嗪基)乙酰基)-,盐酸盐 11-(N-甲基六氢烟酰基)-6,11-二氢-5H-吡啶并(2,3-b)-1,5-苯并二氮杂卓-5-酮 1-(5-甲基-3,4-二氢-2H-吡啶并[2,3-B] [1,4]二氮杂-1-基)乙酮 7,7a,8,9-tetrahydro-5-methyl-5H-pyrido<2,3-b>pyrrole<1,2-d><1,4>diazepin-6,10-dione 2-(3-butoxyphenyl)-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone (S,E)-N-methyl-3-(2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-((3-methylbenzofuran-2-yl)methyl)acrylamide trifluoroacetic acid salt 4-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-d][1,3]diazepin-8-yloxy)butyl methanesulfonate 8-p-tolyl-6,7,9,14,15,16-hexahydroquinoxalino[1,2-a]pyrrolo[2,3-b][1,5]pyridodiazepin-6,7,15-trione 2-(2-furyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methylphenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-phenyl-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(2-thienyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-bromophenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-fluorophenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methoxyphenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methoxyphenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(4-fluorophenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(1-naphthyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 2-(2-furyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 2-(4-bromophenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(2-thienyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 8-chloro-1-methyl-1,2,3,4-tetrahydro-5H-pyrido[2,3-e][1,4]diazepin-5-one 2,3-dihydro-3-hydroxyimino-1-methyl-5-phenyl-1H-pyrido[4,3-e]-1,4-diazepine-2-one 7a,8,9,10-tetrahydro-5-methyldipyrido<2,3-b:1,2-d><1,4>diazepin-6,11(5H,7H)-dione 1-phenyl-2-{(Z)-(4RS)-4-(3-bromo-4,5-dimethoxyphenyl)-1,3,4,5-tetrahydro-2H-pyrido[2,3-b][1,4]diazepin-2-ylidene}-ethanone (+/-)-(R,R)-2-chloro-5-methyl-1,6a,7,8,9,10,10a,11-octahydrobenzo[b]pyrido[2,3-e][1,4]diazepin-4-one (E)-N-methyl-N-((3-methylbenzo[b]thiophen-2-yl)methyl)-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide 2-(3-Methoxyphenyl)-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone 8-Bromo-1,3-dihydro-4,9-dimethyl-2H-pyrido[2,3-b][1,4]diazepin-2-one 5,13-Dimethyl-7,11-diazoniatricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaene 5-(2-Morpholin-4-yl-ethyl)-2-phenyl-3,5-dihydro-pyrido[3,4-b][1,4]diazepin-4-one 4,9-dihydro-10H-pyrido[3,2-b]thieno[3,2-e][1,4]-diazepin-10-one (10S)-11-acetyl-10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,11-hexahydro-3,5,11-triaza-dibenzo[a,d]cyclohepten-9-one (10R)-11-acetyl-10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,11-hexahydro-3,5,11-triaza-dibenzo[a,d]cyclohepten-9-one